

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

UPDATE ANNOUNCEMENT IN RELATION TO (1) DISCLOSEABLE TRANSACTION IN RELATION TO THE CAPITAL INJECTION IN AND DEEMED DISPOSAL OF EQUITY INTEREST IN PENGBO (HAINAN) MEDICAL TECHNOLOGY CO., LTD#; AND (2) DISCLOSEABLE TRANSACTION IN RELATION TO THE GRANT OF THE REPURCHASE RIGHTS

Reference is made to the announcement (the “**Announcement**”) of China Biotech Services Holdings Limited (the “**Company**”) dated 27 February 2025 in relation to, among others, the Capital Injection Agreement and the transactions contemplated thereunder (including, but not limited to, the Capital Injection and the Repurchase Rights). Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcement.

Pursuant to the Capital Injection Agreement entered into among Pengbo (Hainan), Dynamic Healthcare, CBSH Flourish, the Company and Hubei Weiyou on 27 February 2025, if any of the conditions precedent for the payment of the Second Installment is not fulfilled or waived on or before the Long Stop Date, the transaction to subscribe for the registered capital of RMB16,000,000 (equivalent to approximately HK\$17,280,000) at the Second Installment may be terminated by Hubei Weiyou or Pengbo (Hainan) unilaterally. In such event, Hubei Weiyou will subscribe for the registered capital of RMB666,667 (equivalent to approximately HK\$720,000) at the First Installment and completion will take place on the date of such termination.

for identification purposes only

The Board hereby announces that as at the date of this announcement, the conditions precedent for the payment of the Second Installment is not fulfilled or waived and Hubei Weiyou and Pengbo (Hainan) agree to terminate the transaction to subscribe for the registered capital of RMB16,000,000 (equivalent to approximately HK\$17,280,000) at the Second Installment.

As such, Hubei Weiyou has subscribed for the registered capital of RMB666,667 (equivalent to approximately HK\$720,000) at the First Installment and Pengbo (Hainan) will complete the registration of the First Installment accordingly.

The following table set out the registered capital of Pengbo (Hainan) after completion of the registration of the registered capital of RMB666,667 (equivalent to approximately HK\$720,000) at the First Installment:

	Amount of registered capital held (RMB)	Equity interest (%)	Total registered capital of Pengbo (Hainan) (RMB)
CBSH Flourish	150,000,000	99.6	
Hubei Weiyou	666,667	0.4	<u>150,666,667</u>

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 31 March 2025

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.